RNA Analysis/Transcriptomics Market by Technology (Microarray, PCR, NGS, RNAi), by Application (Clinical Diagnostics, Drug Discovery, Toxicogenomics), by End-User (Academic Research, Pharmaceutical and Biotech Companies) - Global Forecast to 2019

The global transcriptomics market is expected to grow at a CAGR of 13.7% during the forecast period of 2014 to 2019 and is estimated to be worth $3,773.0 million by 2019. The transcriptomics market has blatantly grown in the past few years primarily due to the increasing technological advancements in the field of sequencing technologies in transcriptomics research. Similarly, the increasing government and private funding for research coupled with research and development investments by the biotechnology companies are expected to drive the transcriptomics market. The increasing adoption of transcriptomics in the field of biomarker discovery opens new growth avenues with the rising preference of personalized medicine across the globe. However, the higher investment costs that restrict the adoption of transcriptomics products and dearth of skilled professionals are the factors hampering the growth of this market to a certain extent.
The transcriptomics market report covers the transcriptomic technologies, applications and end-users. The technologies market in this report is segmented as microarray, PCR, sequencing technologies which include Sanger sequencing and NGS, and RNAi gene silencing technology. Each of these technologies market is further sub-segmented into reagents, instruments and software. The applications of transcriptomics covered under the scope of this report are clinical diagnostics, drug discovery, and toxicogenomics. The end-users of transcriptomics are pharmaceutical and biotechnology companies, academic research and government institutes, and hospitals and diagnostic centers. This report also discusses the key market drivers, restraints, opportunities, challenges, and trends in the global transcriptomics market and its submarkets.
By 2019, North America will continue to dominate and drive the transcriptomics market, primarily due to the rising preference for personalized medicines which use biomarkers developed with the transcriptomic technologies. On the other hand, the market in Asia-Pacific region is expected to grow at a highest CAGR during the forecast period mainly due to the growing pharmaceutical and biotech industries in China and India. The reduction in funding for research and development coupled with decrease in the investment in research by the pharmaceutical and biotechnology companies in the European region as a means of cost containment is expected to hamper the growth of transcriptomics market in Europe.
The prominent players in the global trancriptomics market are Affymetrix Inc. (U.S.), Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), GE Healthcare (U.S.), Illumina Inc. (U.S.), Qiagen N.V. (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Sigma Aldrich (U.S.), Fluidigm Corporation (U.S.), and Thermofisher Scientific Inc. (U.S.).
Reasons to Buy the Report
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help the firms to garner a greater market share. Firms purchasing this report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for reaping a greater market share.
This report provides insights on the following pointers:
 Market Penetration: Comprehensive information on product portfolios offered by the top players in the transcriptomics market. The report analyzes the transcriptomics market by technology, application, end-user and geography covering North America, Europe, APAC, and RoW
 Product Development/Innovation: Detailed insights on the upcoming trends, research and development activities, and new product launches in the transcriptomics market
 Market Development: Comprehensive information on the lucrative emerging markets for transcriptomics market by technology, application, and end-user by product types
 Market Diversification: Exhaustive information of new products, growing regions, recent developments, and investments in the transcriptomics
 Competitive Assessment: In-depth assessment of market shares, growth strategies, products, manufacturing capabilities, and SWOT analyses of the leading players in the transcriptomics market

TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET SCOPE 18
1.3 MARKETS COVERED 19
1.4 STAKEHOLDERS 20
2 RESEARCH METHODOLOGY 21
2.1 RESEARCH APPROACH 21
2.2 MARKET SIZE ESTIMATION 23
2.3 MARKET CRACKDOWN AND DATA TRIANGULATION 25
2.4 MARKET SHARE ESTIMATION 26
2.5 KEY DATA FROM SECONDARY SOURCES 26
2.6 KEY DATA FROM PRIMARY SOURCES 26
2.6.1 KEY INDUSTRY INSIGHTS 27
2.7 ASSUMPTIONS FOR THE STUDY 27
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 30
4.1 GROWTH POTENTIAL OF THE TRANSCRIPTOMICS MARKET 30
4.2 TRANSCRIPTOMICS TECHNOLOGIES MARKET IN ASIA-PACIFIC 31
4.3 TRANSCRIPTOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 32
4.4 TRANSCRIPTOMICS TECHNOLOGIES MARKET: DEVELOPED VS. DEVELOPING NATIONS 33
4.5 LIFE CYCLE ANALYSIS BY GEOGRAPHY 34
4.6 MARKET CHASM ANALYSIS 35
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 36
5.2 EVOLUTION 36
5.3 MARKET SEGMENTATION 37
5.3.1 TRANSCRIPTOMICS TECHNOLOGIES MARKET, BY TYPE 37
5.3.2 TRANSCRIPTOMICS TECHNOLOGIES MARKET, BY APPLICATION 38
5.3.3 GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET, BY END USER 38
5.4 MARKET DYNAMICS 39
5.5 KEY MARKET DRIVERS 40
5.5.1 GROWING APPLICATIONS OF RNA SEQUENCING IN TRANSCRIPTOMICS RESEARCH TO DRIVE MARKET GROWTH 40
5.5.2 INCREASED RESEARCH AND DEVELOPMENT SPENDING BY BIOTECHNOLOGY COMPANIES TO BOOST TRANSCRIPTOMICS MARKET 40
5.5.3 INCREASING PREFERENCE FOR PERSONALIZED MEDICINE TO FURTHER PROPEL TRANSCRIPTOMICS TECHNOLOGIES MARKET 40
5.5.4 AVAILABILITY OF GOVERNMENT AND PRIVATE FUNDING TO DRIVE TRANSCRIPTOMICS TECHNOLOGIES MARKET 41
5.6 KEY MARKET RESTRAINTS 42
5.6.1 NEED OF HIGH CAPITAL INVESTMENT LIMITS ADOPTION OF TRANSCRIPTOMIC TECHNOLOGIES 42
5.6.2 DEARTH OF SKILLED PROFESSIONALS HINDERING GREATER ADOPTION OF TRANSCRIPTOMIC TECHNOLOGIES 43
5.7 KEY MARKET OPPORTUNITIES 44
5.7.1 SIGNIFICANT OPPORTUNITIES FOR TRANSCRIPTOMIC TECHNOLOGIES IN THE FIELD OF BIOMARKER DISCOVERY 44
5.7.2 EMERGING AND UNTAPPED MARKETS PRESENT OPPORTUNITIES 44
5.7.3 TOXICOGENOMICS AS AN APPLICATION TO OPEN NEW GROWTH AVENUES 44
5.8 KEY CHALLENGES 46
5.8.1 LACK OF EFFECTIVE BIOINFORMATICS TOOLS FOR TRANSCRIPTOMIC ANALYSIS 46
6 INDUSTRY TRENDS 47
6.1 INTRODUCTION 47
6.2 PORTER’S FIVE FORCES ANALYSIS 48
6.2.1 THREAT FROM NEW ENTRANTS 48
6.2.2 THREAT FROM SUBSTITUTES 49
6.2.3 BARGAINING POWER OF BUYERS 49
6.2.4 BARGAINING POWER OF SUPPLIERS 50
6.2.5 INTENSITY OF COMPETITIVE RIVALRY 50
6.3 STRATEGIC BENCHMARKING 50
6.3.1 NEW PRODUCT LAUNCHES 51
7 TRANSCRIPTOMICS TECHNOLOGIES MARKET, BY TYPE 52
7.1 INTRODUCTION 53
7.2 POLYMERASE CHAIN REACTION (PCR) 55
7.2.1 PCR REAGENTS 56
7.2.2 PCR INSTRUMENTS 57
7.2.3 PCR SOFTWARE 58
7.3 SEQUENCING TECHNOLOGIES 59
7.3.1 REAGENTS 61
7.3.2 INSTRUMENTS 62
7.3.3 SOFTWARE 63
7.3.4 SANGER SEQUENCING 64
7.3.5 NEXT-GENERATION SEQUENCING (NGS) 65
7.4 MICROARRAYS 65
7.4.1 MICROARRAY REAGENTS 67
7.4.2 MICROARRAY INSTRUMENTS 68
7.4.3 MICROARRAY SOFTWARE 68
7.5 RNAI GENE SILENCING 70
7.5.1 RNAI GENE SILENCING REAGENTS 71
7.5.2 RNAI GENE SILENCING INSTRUMENTS 72
7.5.3 RNAI GENE SILENCING SOFTWARE 73
8 GLOBAL TRANSCRIPTOMICS MARKET, BY APPLICATION 75
8.1 INTRODUCTION 76
8.1.1 DRUG DISCOVERY 76
8.1.2 CLINICAL DIAGNOSTICS 77
8.1.3 TOXICOGENOMICS 78
9 GLOBAL TRANSCRIPTOMICS MARKET, BY END USER 80
9.1 INTRODUCTION 81
9.2 ACADEMIC RESEARCH & GOVERNMENT INSTITUTES 81
9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 82
9.4 HOSPITALS & DIAGNOSTIC CENTERS 83
10 GLOBAL TRANSCRIPTOMICS MARKET, BY GEOGRAPHY 85
10.1 INTRODUCTION 86
10.2 NORTH AMERICA 88
10.2.1 U.S. 92
10.2.2 CANADA 95
10.2.3 MEXICO 98
10.3 EUROPE 101
10.3.1 GERMANY 104
10.3.2 U.K. 107
10.3.3 FRANCE 110
10.3.4 ITALY 112
10.3.5 SPAIN 115
10.3.6 REST OF EUROPE (ROE) 118
10.4 ASIA-PACIFIC 120
10.4.1 CHINA 124
10.4.2 JAPAN 127
10.4.3 INDIA 130
10.4.4 REST OF ASIA-PACIFIC 132
10.5 REST OF THE WORLD 135
10.5.1 LATIN AMERICA 138
10.5.2 MIDDLE EAST & AFRICA 141
?
11 COMPETITIVE LANDSCAPE 144
11.1 OVERVIEW 144
11.2 MARKET SHARE ANALYSIS 145
11.3 COMPETITIVE SITUATION AND TRENDS 147
11.3.1 NEW PRODUCT LAUNCHES 147
11.3.2 AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS 148
11.3.3 MERGERS & ACQUISITIONS 149
11.3.4 EXPANSIONS 150
11.3.5 PRODUCT ENHANCEMENTS 151
12 COMPANY PROFILES 153
12.1 AFFYMETRIX INC. 154
12.2 AGILENT TECHNOLOGIES, INC. 158
12.3 BIO-RAD LABORATORIES, INC. 161
12.4 GE HEALTHCARE 163
12.5 ILLUMINA, INC. 165
12.6 QIAGEN N.V. 170
12.7 F. HOFFMANN-LA ROCHE LTD. 174
12.8 SIGMA-ALDRICH CORPORATION 176
12.9 THERMO FISHER SCIENTIFIC, INC. 179
12.10 FLUIDIGM CORPORATION 182
*Details on Business Overview, Products & Services, Key Strategy, and Recent Developments might not be captured in case of unlisted companies.

13 APPENDIX 184
13.1 INSIGHTS OF INDUSTRY EXPERTS 184
13.2 DISCUSSION GUIDE 185
13.3 AVAILABLE CUSTOMIZATIONS 189
13.4 RELATED REPORTS 190
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 190